Active Filter(s):
Details:
This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the GelMEDIX pipeline.
Lead Product(s): Regenerative Medicine,Hyaluronic Acid
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: HTL Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2022